Modulation of gene expression by tumor-derived p53 mutants

被引:96
作者
Scian, MJ
Stagliano, KER
Ellis, MA
Hassan, S
Bowman, M
Miles, MF
Deb, SP
Deb, S
机构
[1] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
关键词
D O I
10.1158/0008-5472.CAN-04-1568
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p53 mutants with a single amino acid substitution are overexpressed in a majority of human cancers containing a p53 mutation. Overexpression of the mutant protein suggests that there is a selection pressure on the cell indicative of an active functional role for mutant p53. Indeed, H1299 cells expressing mutant p53-R175H, p53-R273H or p53-D281G grow at a faster rate compared with a control cell line. Using p53-specific small interfering RNA, we show that the growth rate of mutant p53-expressing cells decreases as mutant p53 level decreases, demonstrating that the increased cellular growth is dependent on p53 expression. Increased growth rate is not observed for H1299 cell clones expressing mutant p53-D281G (L22Q/W23S), which has been shown to be defective in transactivation in transient transcriptional assays. This shows that the increased growth rate imparted by mutant p53 in H1299 cells requires the transactivation function of mutant p53. By performing microarray hybridization analyses, we show that constitutive expression of three common p53 mutants (p53-R175H, p53-R273H, and p53-D281G) in H1299 human lung carcinoma cells evokes regulation of a common set of genes, a significant number of which are involved in cell growth regulation. Predictably, H1299 cells expressing p53-D281G (L22Q/W23S) are defective in upregulating a number of these genes. The differences in expression profiles induced by individual p53 mutants in the cells may be representative of the p53 mutants and how they can affect gene expression resulting in the observed "gain of function" phenotypes (i.e., increased growth rate, decreased sensitivity to chemotherapeutic agents, and so forth).
引用
收藏
页码:7447 / 7454
页数:8
相关论文
共 52 条
[1]   Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer [J].
Akahira, J ;
Aoki, M ;
Suzuki, T ;
Moriya, T ;
Niikura, H ;
Ito, K ;
Inoue, S ;
Okamura, K ;
Sasano, H ;
Yaegashi, N .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2197-2202
[2]   Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73 [J].
Bensaad, K ;
Le Bras, M ;
Unsal, K ;
Strano, S ;
Blandino, G ;
Tominaga, O ;
Rouillard, D ;
Soussi, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (12) :10546-10555
[3]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[4]  
BORELLINI F, 1993, J BIOL CHEM, V268, P7923
[5]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[6]   MODULATION OF ACTIVITY OF THE PROMOTER OF THE HUMAN MDR1 GENE BY RAS AND P53 [J].
CHIN, KV ;
UEDA, K ;
PASTAN, I ;
GOTTESMAN, MM .
SCIENCE, 1992, 255 (5043) :459-462
[7]   p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB [J].
Crighton, D ;
Woiwode, A ;
Zhang, C ;
Mandavia, N ;
Morton, JP ;
Warnock, LJ ;
Milner, J ;
White, RJ ;
Johnson, DL .
EMBO JOURNAL, 2003, 22 (11) :2810-2820
[8]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[9]   Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants [J].
Deb, D ;
Scian, M ;
Roth, KE ;
Li, W ;
Keiger, J ;
Chakraborti, AS ;
Deb, SP ;
Deb, S .
ONCOGENE, 2002, 21 (02) :176-189
[10]  
DEJARDIN E, 1995, ONCOGENE, V11, P1835